

Product Datasheet

Felezonexor

Catalog No. **BP-01842** · CAS **1076235-04-5** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-08**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target CRM1; Apoptosis	Research area Cancer
----------------------------------	--------------------------------

Molecular formula **C₁₈H₂₁ClF₃N₃O₃**

Molecular weight **419.8260**

STRUCTURE



DESCRIPTION

CBS9106 (SL-801; Felezonexor) is a reversible oral inhibitor of CRM1 with CRM1 degrading and antitumor activities. CBS9106 arrests the cell cycle and inducing apoptosis in a time- and dose-dependent manner for a broad spectrum of cancer cells.

BIOLOGICAL ACTIVITY

In Vitro

CBS9106 (0.01-10 μM; 72 hours) sensitizes cells to radiation and to suppress the growth of a variety of cancer cell lines. The estimated IC₅₀ values range from 22.3 or 35.6 nM in multiple myeloma (MM).1S or RPMI-8226 cells and from 3 to 278 nM in 60 other human cancer cell lines.

CBS9106 (1-400 nM; 24 hours) decreases CRM1 protein expression levels in a dose-dependent manner.

In Vivo

CBS9106 (31.25-62.5 mg/kg for 5 times weekly, 125 mg/kg for 3 times weekly; p.o.; 2 weeks) significantly suppresses tumor growth at dose levels of 62.5 or 125 mg/kg in mice bearing human MM xenograft models.

SOLUBILITY

Soluble in DMSO : 100 mg/mL

REFERENCES

[1]. Sakakibara K, Saito N, Sato T, et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011;118(14):3922-3931. doi:10.1182/blood-2011-01-333138